New drug cocktail aims to stop sarcoma from coming back
NCT ID NCT01746238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety and best dose of adding bevacizumab to standard chemotherapy and radiation for people with soft tissue sarcoma that can be removed by surgery. The goal is to see if this combination can reduce the chance of the cancer returning after surgery. The study involved 14 adults with intermediate- or high-grade sarcoma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?